Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Ramya, Muddasani"'
Autor:
Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5671-5680 (2021)
Abstract Background Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better und
Externí odkaz:
https://doaj.org/article/3247895c6c634ff285bccc140d3b7306
Publikováno v:
Clinical Case Reports, Vol 8, Iss 5, Pp 877-882 (2020)
Abstract Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B‐cell receptor pathway. We present a patient with atypical CLL who had a significant response to
Externí odkaz:
https://doaj.org/article/f8c8f3bd41e049c2a0896b8d75f0d748
Autor:
Alexander Chehrazi-Raffle, Ramya Muddasani, Nazli Dizman, JoAnn Hsu, Luis Meza, Zeynep B. Zengin, Jasnoor Malhotra, Neal Chawla, Tanya Dorff, Tania Contente-Cuomo, Devin Dinwiddie, Bradon R. McDonald, Timothy McDaniel, Jeffrey M. Trent, Frederick L. Baehner, Muhammed Murtaza, Sumanta K. Pal
Publikováno v:
JCO Precision Oncology.
PURPOSE Circulating tumor DNA (ctDNA) has been validated across multiple indications in the adjuvant and surveillance settings. We evaluated whether targeted digital sequencing (TARDIS) may distinguish a partial response (PR) from a complete response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88c2c745eccc177c9a704c115820ed96
https://doi.org/10.1200/po.22.00543
https://doi.org/10.1200/po.22.00543
Autor:
Sumanta K. Pal, Neeraj Agarwal, Toni K. Choueiri, Divyam Goel, Nityam Rathi, Benjamin L. Maughan, Lesli Kiedrowski, Errol J. Philip, Neal Chawla, Jasnoor Malhotra, Sabrina Salgia, Ramya Muddasani, Alexander Chehrazi-Raffle, Luis Meza, Joann Hsu, Nazli Dizman, Nicholas J. Salgia, Caroline Weipert, Zeynep B. Zengin
Patient characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23f69e25dac01722c2843f97ae2d9161
https://doi.org/10.1158/1078-0432.22480646.v1
https://doi.org/10.1158/1078-0432.22480646.v1
Autor:
Sumanta K. Pal, Neeraj Agarwal, Toni K. Choueiri, Divyam Goel, Nityam Rathi, Benjamin L. Maughan, Lesli Kiedrowski, Errol J. Philip, Neal Chawla, Jasnoor Malhotra, Sabrina Salgia, Ramya Muddasani, Alexander Chehrazi-Raffle, Luis Meza, Joann Hsu, Nazli Dizman, Nicholas J. Salgia, Caroline Weipert, Zeynep B. Zengin
Change in alterations across time points
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a356febcfa85f54de1a458cf9aafc7e8
https://doi.org/10.1158/1078-0432.22480652.v1
https://doi.org/10.1158/1078-0432.22480652.v1
Autor:
Sumanta K. Pal, Neeraj Agarwal, Toni K. Choueiri, Divyam Goel, Nityam Rathi, Benjamin L. Maughan, Lesli Kiedrowski, Errol J. Philip, Neal Chawla, Jasnoor Malhotra, Sabrina Salgia, Ramya Muddasani, Alexander Chehrazi-Raffle, Luis Meza, Joann Hsu, Nazli Dizman, Nicholas J. Salgia, Caroline Weipert, Zeynep B. Zengin
Purpose:The role of circulating cell-free tumor DNA (ctDNA) as an adjunct to tissue genomic profiling is poorly defined in metastatic renal cell carcinoma (mRCC). In this study, we aim to validate previous findings related to genomic alteration (GA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0480fff840b8488b662c5df891a3c5f0
https://doi.org/10.1158/1078-0432.c.6530498
https://doi.org/10.1158/1078-0432.c.6530498
Autor:
Zeynep B, Zengin, Ameish, Govindarajan, Nicholas, Salgia, Nicolas, Sayegh, Nishita, Tripathi, Ramya, Muddasani, Alex, Chehrazi-Raffle, Matthew, Feng, Benjamin D, Mercier, Colton, Ladbury, Claire, Hao, Sabrina, Salgia, Neal, Chawla, Luis, Meza, Jasnoor, Malhotra, Nazli, Dizman, JoAnn, Hsu, Daniela V, Castro, Regina, Barragan-Carrillo, Hedyeh, Ebrahimi, Errol J, Philip, Mark, Chang, Jiaming, Zhang, Sara, Byron, Yung, Lyou, Tanya, Dorff, Sumanta K, Pal, Savita, Dandapani
Publikováno v:
European Urology Oncology.
Stereotactic body radiation therapy (SBRT) has been shown to be safe and effective for delaying systemic treatment change among patients with metastatic renal cell carcinoma (mRCC). In this study, we sought to assess the genomic signatures of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::916b4ec41a1a6d2b00f00770661008c4
https://doi.org/10.1016/j.euo.2022.11.006
https://doi.org/10.1016/j.euo.2022.11.006
Publikováno v:
Kidney Cancer. 5:9-20
In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::379147228f4dff221fa30b4d6dd4c855
https://doi.org/10.3233/kca-200105
https://doi.org/10.3233/kca-200105
Autor:
Nazli Dizman, Luis Meza, Paulo Bergerot, Marice Alcantara, Tanya Dorff, Yung Lyou, Paul Frankel, Yujie Cui, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal Chawla, Alex Chehrazi-Raffle, Ramya Muddasani, John Gillece, Lauren Reining, Jeff Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Sarah K. Highlander, Sumanta K. Pal
Publikováno v:
Nature medicine. 28(4)
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3378fa6e57d09b2c6e662de7b7528b79
https://pubmed.ncbi.nlm.nih.gov/35899808
https://pubmed.ncbi.nlm.nih.gov/35899808
Autor:
Nicholas Salgia, Alex Chehrazi-Raffle, Ramya Muddasani, Luis Meza, Sana Ali, Zeynep Busra Zengin, Sumanta K. Pal
Publikováno v:
Urologic oncology. 40(2)
The management of urothelial carcinoma (UC) has rapidly advanced in recent years with new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However, while many UC tumors contain potentially actionable mutations, the role for ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a12441272cc29684b80e18d4890dff18
https://pubmed.ncbi.nlm.nih.gov/34840077
https://pubmed.ncbi.nlm.nih.gov/34840077